Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Nadia T MirakianCONICET-Universidad de Buenos Aires, Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.
Rubén F IáconoUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología, Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.
Viviana B PulidoCONICET-Universidad de Buenos Aires, Instituto de Estudios de la Inmunidad Humoral (IDEHU), Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.
Matías A PibuelUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología, Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.ORCID 0000-0003-4769-6570
Silvina L LompardíaUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología, Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.
Laura C LaurellaCONICET-Universidad de Buenos Aires, Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.
Nicolás Pérez-MauadCONICET-Universidad de Buenos Aires, Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.ORCID 0009-0009-7348-7976
Cesar A N CatalánFacultad de Bioquímica, Química y Farmacia, Instituto de Química Orgánica, Universidad Nacional de Tucumán, San Miguel de Tucumán, Tucumán T4000INI, Argentina.ORCID 0000-0001-7409-5303
Tomás LombardoUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología, Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.
Martín M LedesmaUnidad de Conocimiento Traslacional, Hospital de Alta Complejidad del Bicentenario Esteban Echeverría, Monte Grande B1842DOL, Argentina.ORCID 0000-0002-9080-2108
Adriana CarlucciUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Tecnología Farmacéutica, Instituto de Tecnología Farmacéutica u Biofarmacia (InTecFYB, UBA), Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.
Valeria P SülsenCONICET-Universidad de Buenos Aires, Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.ORCID 0000-0002-9322-5748
Daniela L PapademetrioUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología, Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.
Funding
National Agency for Science and Technology Promotion PICT-2019-00736National Agency for Science and Technology Promotion PICT-2021-0051National Agency for Science and Technology Promotion PICTO-2021-0018University of Buenos Aires UBACYT 20020220300118BAUniversity of Buenos Aires UBACYT 392 20020220400220BA
6 · The paper itself
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies, highlighting the need to identify novel bioactive compounds with antitumor potential. Natural products constitute a valuable source of molecules with anticancer activity. In this study, we performed a comparative analysis of two classes of natural compounds-sesquiterpene lactones (achillin and polymatin A) and naphthoquinones (α, β-lapachone and lapachol)-in human PDAC cell lines on cell proliferation, metabolic activity and cell death induction and early mitochondrial alterations. Achillin showed limited antiproliferative, metabolic, and cytotoxic activity, whereas polymatin A exhibited activity in the micromolar range, yielding LC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
In Vitro Evaluation of Natural Sesquiterpene Lactones and Naphthoquinones Against Pancreatic Ductal Adenocarcinoma Cells. · full record | Socratic